Sanjivani Paranteral Ltd.
BSE: SANJIVIN · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sanjivani Paranteral Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanjivani Paranteral Limited is a Mumbai-based pharmaceutical company specialising in the manufacturing and export of parenteral and oral solid dosage formulations. Its product portfolio spans therapeutic categories including antibiotics, analgesics, and cardiovascular drugs, catering primarily to international markets.
Business Model
The company generates revenue through the manufacturing and export of generic pharmaceutical formulations and by providing contract manufacturing services to global pharmaceutical players.
Growth Outlook
Growth is driven by the expansion of manufacturing capabilities to include specialised injectable products and the continued scaling of contract manufacturing services for international clients.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international regulatory standards at its manufacturing facilities, which is critical for its export-oriented business model.
- Geopolitical Instability. As a significant exporter to regions like the CIS and Africa, the company is susceptible to political and economic instability in these markets.
- Currency Fluctuation. Heavy reliance on export markets exposes the company to volatility in foreign exchange rates, which can impact profit margins.
- Competitive Pricing. The generic pharmaceutical sector is highly competitive, potentially putting pressure on pricing and margins for the company's core product offerings.
Start your research today
Unlock AI insights, financials, peers and live data on Sanjivani Paranteral Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹72 Cr
TTM · consolidated
NET PROFIT
₹10 Cr
TTM · consolidated
EPS
₹7.94
TTM · consolidated
RETURN ON EQUITY
23.9%
TTM · consolidated
P/E
20.8x
Q4 FY26 · consolidated
EV/EBITDA
15.7x
Q4 FY26 · consolidated
EBITDA MARGIN
20.1%
TTM · consolidated
NET PROFIT MARGIN
4.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sanjivani Paranteral Ltd.SANJIVIN | ₹212 Cr | 20.79 | 15.66 | 24.6% | 20.1% | 23.9% | 26.3% | -24.9% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Sanjivani Paranteral Ltd.
BSE: SANJIVIN · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sanjivani Paranteral Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanjivani Paranteral Limited is a Mumbai-based pharmaceutical company specialising in the manufacturing and export of parenteral and oral solid dosage formulations. Its product portfolio spans therapeutic categories including antibiotics, analgesics, and cardiovascular drugs, catering primarily to international markets.
Business Model
The company generates revenue through the manufacturing and export of generic pharmaceutical formulations and by providing contract manufacturing services to global pharmaceutical players.
Growth Outlook
Growth is driven by the expansion of manufacturing capabilities to include specialised injectable products and the continued scaling of contract manufacturing services for international clients.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international regulatory standards at its manufacturing facilities, which is critical for its export-oriented business model.
- Geopolitical Instability. As a significant exporter to regions like the CIS and Africa, the company is susceptible to political and economic instability in these markets.
- Currency Fluctuation. Heavy reliance on export markets exposes the company to volatility in foreign exchange rates, which can impact profit margins.
- Competitive Pricing. The generic pharmaceutical sector is highly competitive, potentially putting pressure on pricing and margins for the company's core product offerings.
Start your research today
Unlock AI insights, financials, peers and live data on Sanjivani Paranteral Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹72 Cr
TTM · consolidated
NET PROFIT
₹10 Cr
TTM · consolidated
EPS
₹7.94
TTM · consolidated
RETURN ON EQUITY
23.9%
TTM · consolidated
P/E
20.8x
Q4 FY26 · consolidated
EV/EBITDA
15.7x
Q4 FY26 · consolidated
EBITDA MARGIN
20.1%
TTM · consolidated
NET PROFIT MARGIN
4.2%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26